Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Uveal Melanoma: early-phase trial registry
12 of 30 indexed Uveal Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 12 currently recruiting · #519 of 28,707 conditions by registered trial count
Uveal Melanoma: 30 US clinical trials tracked, 12 recruiting.
Uveal Melanoma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.
Enrollment posture brief
Registry condition uveal-melanoma
OPEN 12 | RECR 40% | LATE 3 | EARLY 21 | RANK #519 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Uveal Melanoma lists 12 open slots (40% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Uveal Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Uveal Melanoma recruits in line with its size-band peers.
12 of 30 indexed trials (40%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Uveal Melanoma trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 30 trials (6.7%). 26 distinct sponsors appear on at least one study for this condition label.
-
Most Uveal Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 30 trials that report a genuine target (sentinel values excluded). 19 of those (63.3%) plan for fewer than 100 participants.
-
Uveal Melanoma research is mostly interventional.
26 interventional and 4 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
NCT07015190
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Aura Biosciences
NCT06007690
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility
NCT06805825
Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami
NCT06932757
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Diwakar Davar
NCT06070012
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
California Pacific Medical Center Research Institute
NCT05077280
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05524935
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05607095
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Anusha Kalbasi
NCT04119024
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Modulation Therapeutics
NCT05496686
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Massachusetts General Hospital
NCT07364474
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics
NCT05812027
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group
NCT03611868
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
NCT05907954
A Prospective Natural History Study in Uveal Melanoma
Columbia University
NCT04588662
Psychoeducation for Uveal Melanoma
Jonsson Comprehensive Cancer Center
NCT06075589
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
NCT03635632
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT04645680
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore
NCT03070392
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Novartis Pharmaceuticals
NCT01430416
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
AstraZeneca
NCT01974752
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT03207347
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
NCT02223819
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
NCT04551352
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Iconic Therapeutics
NCT02771340
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
NCT03922880
New Biopsy Technique for Uveal Melanoma
Greater Houston Retina Research
NCT01924923
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 9 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Uveal Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Uveal Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Uveal Melanoma page
30 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Uveal Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Uveal Melanoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Uveal Melanoma condition card totals 30 registered trials; most-linked intervention Darovasertib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.